Skip to content
GLP-1 / EVIDENCE MONITOR

Semaglutide

Study findings, populations and outcomes, with a direct line back to each source.

38 cited sources133 recorded findingsStudy findings updated

AI-assisted research summary. These summaries are for general information. Read the original source for the full study and its limitations.

THE SHORT VERSION

What’s worth knowing.

The key findings, what they mean, and the context that matters.

THE HEADLINE TAKEAWAY-11.85%average difference between groups

Subcutaneous semaglutide reduced weight but raised discontinuation

In adults with overweight or obesity without type 2 diabetes, subcutaneous semaglutide produced greater percentage body-weight loss than placebo; the mean difference was -11.85%.

Discontinuation because of adverse events was also higher with semaglutide than placebo. The treatment timeframe is not available in this summary.

See the evidence

Percentage change in body weight with subcutaneous semaglutide versus placebo in adults with overweight or obesity without type 2 diabetes

MD -11.85%
95% CI: -12.81% to -10.90%

Naz, Faryal et al.. Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.. Medicine. 2026.

Added

Treatment discontinuation due to adverse events with subcutaneous semaglutide versus placebo in adults with overweight or obesity without type 2 diabetes

RR 2.62
95% CI: 1.70-4.03

Naz, Faryal et al.. Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.. Medicine. 2026.

Added

02

Semaglutide lowered serious kidney-event hazard versus placebo

Across the pooled SELECT, FLOW, and SOUL trials, semaglutide had a lower hazard than placebo of persistent reduction of at least 50% in estimated kidney function, kidney failure, or kidney- or cardiovascular-related death.

This prespecified analysis pooled trials that differed in participant characteristics and semaglutide dose and route; a single common clinical population is not available in this summary. A narrower kidney composite also favored semaglutide.

See the evidence

Primary composite of persistent ≥50% eGFR reduction, kidney failure, kidney-related death, or cardiovascular-related death with semaglutide versus placebo in the prespecified pooled SELECT, FLOW, and SOUL analysis; 973 versus 1134 first events. The trials differed in participants' baseline characteristics and in semaglutide dose and route.

HR 0.84
95% CI: 0.77-0.91

Mann, Johannes F E et al.. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.. The lancet. Diabetes & endocrinology. 2026.

Added

Narrower secondary kidney composite excluding cardiovascular-related death with semaglutide versus placebo in the prespecified pooled SELECT, FLOW, and SOUL analysis; 347 versus 416 first events. The trials differed in participants' baseline characteristics and in semaglutide dose and route.

HR 0.80
95% CI: 0.69-0.92

Mann, Johannes F E et al.. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.. The lancet. Diabetes & endocrinology. 2026.

Added

03

Reduced-insulin semaglutide strategy improved several diabetes outcomes

At 40 weeks, semaglutide 2.0 mg plus dose-reduced insulin glargine lowered the blood-glucose measure HbA1c and body weight more than dose-titrated insulin glargine. Severe episodes of low blood glucose (hypoglycaemia) occurred at a lower rate.

This comparison involved people with type 2 diabetes and overweight. Gastrointestinal event counts were higher with the semaglutide strategy, but they were events rather than participant-level incidence rates.

See the evidence

HbA1c reduction with semaglutide 2.0 mg plus dose-reduced insulin glargine versus dose-titrated insulin glargine at 40 weeks

ETD -0.74%
95% CI: -0.90% to -0.59%

Rodbard, Helena W et al.. Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).. Diabetes, obesity & metabolism. 2026.

Added

Body-weight change with semaglutide 2.0 mg plus dose-reduced insulin glargine versus dose-titrated insulin glargine at 40 weeks

ETD -8.5 kg
95% CI: -9.5 to -7.4 kg

Rodbard, Helena W et al.. Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).. Diabetes, obesity & metabolism. 2026.

Added

Severe hypoglycaemia occurred at a lower rate with semaglutide 2.0 mg plus dose-reduced insulin glargine versus dose-titrated insulin glargine at 40 weeks (p=0.02).

Rate ratio 0.45
95% CI: 0.23-0.87

Rodbard, Helena W et al.. Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).. Diabetes, obesity & metabolism. 2026.

Added

Gastrointestinal adverse-event counts were higher with semaglutide 2.0 mg plus dose-reduced insulin glargine than with dose-titrated insulin glargine; these are event counts rather than participant-level incidence rates, and the abstract reported no new safety concerns.

310 vs. 32 events

Rodbard, Helena W et al.. Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).. Diabetes, obesity & metabolism. 2026.

Added

04

Weight regain followed stopping semaglutide 2.4 mg

7.19%

Across six studies, pooled mean body-weight regain from the end of treatment to follow-up after stopping semaglutide 2.4 mg was 7.19%.

The follow-up interval is not available in this summary, so the estimate does not show the monthly rate of regain or when any particular weight level was reached.

See the evidence

Pooled mean percentage body-weight regain from end of treatment to follow-up after stopping semaglutide 2.4 mg, based on six studies

7.19%
95% CI: 6.42-7.96

Patel, Henna et al.. Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.. Cureus. 2026.

Added

05

Observational evidence raises an optic-nerve safety signal

In observational cohorts, semaglutide was associated with more nonarteritic anterior ischemic optic neuropathy than non-semaglutide treatment.

Heterogeneity was high, and randomized trials were requested for a clear conclusion. The reported interval for the overweight-or-obesity subgroup included no difference, so this remains an uncertain association rather than proof of causation.

See the evidence

NAION risk with semaglutide versus non-semaglutide treatment in a meta-analysis of observational cohorts; heterogeneity was high (I2=91%), and the authors stated that randomized trials are needed for a clear conclusion.

RE 1.93
95% CI: 1.22-3.08

Khani, Elnaz et al.. Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.. Journal of clinical pharmacology. 2026.

Added

NAION association among individuals with overweight or obesity; the result was not statistically significant and heterogeneity was high (I2=83.98%).

RE 1.68
95% CI: 0.72-3.91

Khani, Elnaz et al.. Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.. Journal of clinical pharmacology. 2026.

Added

Association between semaglutide use and NAION among individuals with diabetes; subgroup heterogeneity was high (I2=88.26%).

RE 1.84
95% CI: 1.21-2.80

Khani, Elnaz et al.. Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.. Journal of clinical pharmacology. 2026.

Added

06

Fatty-liver inflammation resolved more often; pooled scarring improvement was uncertain

114%higher relative risk

Versus placebo, subcutaneous semaglutide had a 114% higher relative risk of fatty-liver inflammation resolving without liver scarring progressing. For pooled improvement in liver-scarring stage with semaglutide versus placebo, the reported interval included no difference.

The meta-analysis covered metabolic dysfunction-associated fatty-liver disease or fatty-liver inflammation. A separate review cautioned that whether liver-tissue improvement reduces clinical outcomes remains unproven.

See the evidence

114% higher relative risk, calculated from RR 2.14. This is not an absolute percentage-point difference.

NASH resolution without fibrosis progression with subcutaneous semaglutide versus placebo

RR 2.14
95% CI: 1.44-3.17

Khan, Suleman et al.. Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.. Medicine. 2026.

Added

Fibrosis-stage improvement with subcutaneous semaglutide versus placebo; the pooled result was not statistically significant

RR 1.14
95% CI: 0.63-2.05

Khan, Suleman et al.. Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.. Medicine. 2026.

Added

Fibrosis improvement by at least one stage with semaglutide versus placebo after 72 weeks in MASH; the relationship between treatment-induced histologic improvement and reduced clinical outcomes remains unproven.

37% vs 22%

Ayoub, Malek et al.. Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.. Alimentary pharmacology & therapeutics. 2026.

Added

Study-specific findings. Different populations, treatments and follow-up periods can produce different results.

THE RESEARCH, AS IT ARRIVES

Latest studies.

The newest findings added to this collection.
The learning from each, already distilled.

  1. STUDY 01Findings added
    TL;DR

    Semaglutide subgroup showed weight loss during antipsychotic treatment

    In randomized trials of adjunctive GLP-1 receptor agonists for antipsychotic-treated patients, the semaglutide subgroup showed reductions in body weight and BMI.

    The comparator underlying the semaglutide subgroup estimates is not available in this summary, so their numerical magnitudes are not presented. Between-agent subgroup differences were reported.

    Study details & original results

    Moubarak, Elsayed S et al.. Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.. Journal of psychopharmacology (Oxford, England). 2026.

    Body-weight reduction with semaglutide in a GLP-1 RA type subgroup analysis of randomized trials involving antipsychotic-treated patients; between-agent subgroup differences for weight and BMI were significant at p<0.05.

    MD -11.06 kg

    BMI reduction with semaglutide in a GLP-1 RA type subgroup analysis of randomized trials involving antipsychotic-treated patients; between-agent subgroup differences for weight and BMI were significant at p<0.05.

    MD -3.60 kg/m²

    Citation in Semaglutide
  2. STUDY 02Findings added
    TL;DR

    Tirzepatide produced more weight loss than semaglutide

    -20.2% vs -13.7%

    In an open-label randomized active-controlled trial of adults with overweight or obesity, mean body-weight change at 72 weeks was -20.2% with tirzepatide versus -13.7% with semaglutide.

    Retrospective cohorts also favored tirzepatide, but effects were smaller and heterogeneous, and several cohorts had serious confounding-related bias.

    Study details & original results

    Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.

    Mean body-weight change at 72 weeks with tirzepatide versus semaglutide in a phase 3b open-label, randomized, active-controlled trial of adults with overweight or obesity.

    -20.2% vs -13.7%

    Range of adjusted between-group weight-loss differences across retrospective real-world cohorts; the advantage was smaller than in the trial and most pronounced at stringent weight-reduction thresholds. Substantial heterogeneity precluded meta-analysis, and four cohorts had serious risk of bias, principally from unadjusted confounding.

    approximately 2.3-4.4 percentage points favoring tirzepatide

    Citation in Semaglutide
  3. STUDY 03Findings added
    TL;DR

    Semaglutide was followed by weight loss after bariatric surgery

    9.02% total weight loss

    Among adults starting an incretin receptor agonist at least one year after metabolic bariatric surgery, semaglutide was associated with 9.02% total weight loss at 12 months.

    Heterogeneity across studies was substantial. At 6 months, tirzepatide produced greater total weight loss than semaglutide, but that pooled comparison was also heterogeneous.

    Study details & original results

    Santos-Pereira, Mariana et al.. Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.

    Total weight loss at 12 months with semaglutide in adults treated with an incretin receptor agonist at least one year after metabolic bariatric surgery; substantial heterogeneity across studies requires cautious interpretation.

    9.02% total weight loss

    Mean difference in total weight loss at 6 months for tirzepatide versus semaglutide after metabolic bariatric surgery; substantial heterogeneity across studies requires cautious interpretation.

    MD 4.23% favoring tirzepatide

    Citation in Semaglutide
  4. STUDY 04Findings added
    TL;DR

    Weight returned after semaglutide or tirzepatide was stopped

    1.04 kg/month

    Across semaglutide or tirzepatide studies, estimated weight regain after discontinuation was 1.04 kg/month.

    Observed follow-up ranged from 4 to 52 weeks. Both projected milestones used a constant linear-regain model, but only the projected return to baseline extended beyond the maximum observed follow-up.

    Study details & original results

    Kow, Chia Siang et al.. Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.

    Estimated monthly weight regain after discontinuation across semaglutide or tirzepatide studies with observed follow-up ranging from 4 to 52 weeks; this pooled estimate is not semaglutide-specific.

    1.04 kg/month
    95% CrI: 0.80-1.29

    Projected time to regain 50% of the initial weight loss after semaglutide or tirzepatide discontinuation, based on a constant linear-regain model; estimates beyond 52 weeks were extrapolated and require cautious interpretation.

    7.50 months
    95% CrI: 5.05-10.57

    Projected time to return to baseline weight after semaglutide or tirzepatide discontinuation, based on a constant linear-regain model; this exceeds the observed follow-up and is a model-based extrapolation.

    15.00 months
    95% CrI: 10.10-21.13

    Citation in Semaglutide
4 of 38 study updates

Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.

WHEN YOU WANT TO GO DEEPER
See all 133 findingsOriginal results, comparisons and study details.
38 of 38 source groupsFindings stay together with their study.
SOURCE 382 findings

Moubarak, Elsayed S et al.. Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.. Journal of psychopharmacology (Oxford, England). 2026.

Body-weight reduction with semaglutide in a GLP-1 RA type subgroup analysis of randomized trials involving antipsychotic-treated patients; between-agent subgroup differences for weight and BMI were significant at p<0.05.

Added
MD -11.06 kgSource [38]

BMI reduction with semaglutide in a GLP-1 RA type subgroup analysis of randomized trials involving antipsychotic-treated patients; between-agent subgroup differences for weight and BMI were significant at p<0.05.

Added
MD -3.60 kg/m²Source [38]
SOURCE 372 findings

Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.

Mean body-weight change at 72 weeks with tirzepatide versus semaglutide in a phase 3b open-label, randomized, active-controlled trial of adults with overweight or obesity.

Added
-20.2% vs -13.7%Source [37]

Range of adjusted between-group weight-loss differences across retrospective real-world cohorts; the advantage was smaller than in the trial and most pronounced at stringent weight-reduction thresholds. Substantial heterogeneity precluded meta-analysis, and four cohorts had serious risk of bias, principally from unadjusted confounding.

Added
approximately 2.3-4.4 percentage points favoring tirzepatideSource [37]
SOURCE 362 findings

Santos-Pereira, Mariana et al.. Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.

Total weight loss at 12 months with semaglutide in adults treated with an incretin receptor agonist at least one year after metabolic bariatric surgery; substantial heterogeneity across studies requires cautious interpretation.

Added
9.02% total weight lossSource [36]

Mean difference in total weight loss at 6 months for tirzepatide versus semaglutide after metabolic bariatric surgery; substantial heterogeneity across studies requires cautious interpretation.

Added
MD 4.23% favoring tirzepatideSource [36]
SOURCE 342 findings

Moiz, Areesha et al.. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.. Annals of internal medicine. 2026.

Placebo-subtracted weight loss with subcutaneous semaglutide in an updated systematic review of RCTs among adults with overweight or obesity without diabetes; heterogeneity precluded quantitative synthesis.

Added
up to -14.8%95% CI: -16.2% to -13.4%Source [34]

Placebo-subtracted weight loss with oral semaglutide in an updated systematic review of RCTs among adults with overweight or obesity without diabetes; heterogeneity precluded quantitative synthesis.

Added
up to -14.3%95% CI: -17.2% to -11.4%Source [34]
SOURCE 354 findings

Kow, Chia Siang et al.. Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.

Estimated weight loss at treatment cessation across six studies of semaglutide or tirzepatide; this pooled estimate is not semaglutide-specific.

Added
15.35 kg95% CrI: 11.18-19.60Source [35]

Estimated monthly weight regain after discontinuation across semaglutide or tirzepatide studies with observed follow-up ranging from 4 to 52 weeks; this pooled estimate is not semaglutide-specific.

Added
1.04 kg/month95% CrI: 0.80-1.29Source [35]
All 4 findings from this source

Projected time to regain 50% of the initial weight loss after semaglutide or tirzepatide discontinuation, based on a constant linear-regain model; estimates beyond 52 weeks were extrapolated and require cautious interpretation.

Added
7.50 months95% CrI: 5.05-10.57Source [35]

Projected time to return to baseline weight after semaglutide or tirzepatide discontinuation, based on a constant linear-regain model; this exceeds the observed follow-up and is a model-based extrapolation.

Added
15.00 months95% CrI: 10.10-21.13Source [35]
SOURCE 328 findings

McIntyre, Roger S et al.. Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.. JAMA psychiatry. 2026.

Four-year all-cause mortality among propensity-score-matched adults with serious mental illness initiating any GLP-1 RA versus an SGLT2 inhibitor; this is a class-level, not semaglutide-specific, estimate.

Added
HR 0.7695% CI: 0.74-0.78Source [32]

Absolute four-year all-cause mortality difference among matched adults with serious mental illness initiating any GLP-1 RA versus an SGLT2 inhibitor; this is a class-level estimate.

Added
4.91% vs 6.45%; ARD -1.54 percentage points95% CI: -1.68 to -1.39 percentage pointsSource [32]
All 8 findings from this source

One-year all-cause mortality in a separately matched serious-mental-illness cohort initiating any GLP-1 RA versus an SGLT2 inhibitor; this is a class-level, not semaglutide-specific, estimate.

Added
RR 0.5295% CI: 0.49-0.54Source [32]

Absolute one-year all-cause mortality difference in a separately matched serious-mental-illness cohort initiating any GLP-1 RA versus an SGLT2 inhibitor; this is a class-level estimate.

Added
1.46% vs 2.84%; ARD -1.38 percentage points95% CI: -1.47 to -1.29 percentage pointsSource [32]

Three-point MACE with semaglutide versus SGLT2 inhibitor initiation among participants with serious mental illness and type 2 diabetes.

Added
HR 0.7795% CI: 0.76-0.79Source [32]

Mortality with semaglutide versus SGLT2 inhibitor initiation in the major-depressive-disorder subgroup with type 2 diabetes in an exploratory 10-year analysis.

Added
RR 0.5595% CI: 0.53-0.56Source [32]

Mortality with semaglutide versus SGLT2 inhibitor initiation in the bipolar-disorder subgroup with type 2 diabetes in an exploratory 10-year analysis.

Added
RR 0.5795% CI: 0.51-0.63Source [32]

Mortality with semaglutide versus SGLT2 inhibitor initiation in the schizophrenia subgroup with type 2 diabetes in an exploratory 10-year analysis.

Added
RR 0.6795% CI: 0.59-0.75Source [32]
SOURCE 335 findings

Zinzi, Alessia et al.. Semaglutide Exposure During Pregnancy: Results from the FAERS Database.. Pharmaceuticals (Basel, Switzerland). 2026.

FAERS cases involving semaglutide use during pregnancy from 2017 through 2025; these are report counts rather than an incidence estimate.

Added
249 cases; 922 adverse eventsSource [33]

Proportion of reported adverse events involving abortion or pregnancy loss; this is a proportion of reported events, not the risk among exposed pregnancies.

Added
All 5 findings from this source

FAERS reporting odds for pregnancy, puerperium, and perinatal conditions with semaglutide versus other medications; this is a disproportionality signal and not a causal risk estimate.

Added
ROR 1.5995% CI: 1.37-1.86Source [33]

FAERS reporting odds for gastrointestinal disorders with semaglutide versus other medications in pregnancy-related reports; this is a disproportionality signal and not a causal risk estimate.

Added
ROR 1.7295% CI: 1.38-2.15Source [33]

SMQ-based FAERS reporting odds for termination of pregnancy and risk of abortion with semaglutide versus other medications; this is a reporting signal and does not establish increased clinical risk or causation.

Added
ROR 3.7195% CI: 3.07-4.48Source [33]
SOURCE 313 findings

Banerjee, Mainak et al.. Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.. Obesity (Silver Spring, Md.). 2026.

Major adverse liver outcomes with tirzepatide versus injectable semaglutide among adults with overweight or obesity and type 2 diabetes over a median follow-up of approximately 17 months; no significant difference was observed.

Added
HR 1.04; IR 4.05 vs. 4.04 per 1000 PY95% CI: 0.88-1.23Source [31]

Major adverse liver outcomes with tirzepatide versus injectable semaglutide in the MASLD subgroup; the abstract reported a comparable risk profile.

Added
HR 1.03; IR 9.97 vs. 10.03 per 1000 PY95% CI: 0.75-1.42Source [31]
All 3 findings from this source

Major adverse liver outcomes with tirzepatide versus injectable semaglutide in the as-treated sensitivity analysis.

Added
HR 0.9895% CI: 0.80-1.21Source [31]
SOURCE 303 findings

Khani, Elnaz et al.. Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.. Journal of clinical pharmacology. 2026.

NAION risk with semaglutide versus non-semaglutide treatment in a meta-analysis of observational cohorts; heterogeneity was high (I2=91%), and the authors stated that randomized trials are needed for a clear conclusion.

Added
RE 1.9395% CI: 1.22-3.08Source [30]

Association between semaglutide use and NAION among individuals with diabetes; subgroup heterogeneity was high (I2=88.26%).

Added
RE 1.8495% CI: 1.21-2.80Source [30]
All 3 findings from this source

NAION association among individuals with overweight or obesity; the result was not statistically significant and heterogeneity was high (I2=83.98%).

Added
RE 1.6895% CI: 0.72-3.91Source [30]
SOURCE 281 finding

Ayoub, Malek et al.. Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.. Alimentary pharmacology & therapeutics. 2026.

Fibrosis improvement by at least one stage with semaglutide versus placebo after 72 weeks in MASH; the relationship between treatment-induced histologic improvement and reduced clinical outcomes remains unproven.

Added
37% vs 22%Source [28]
SOURCE 291 finding

Plutzky, Jorge et al.. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.. Circulation. 2026.

Semaglutide-associated change in hsCRP at 104 weeks among patients with established atherosclerotic cardiovascular disease and overweight or obesity but without diabetes in the prespecified SELECT analysis.

Added
-37.8% at 104 weeksSource [29]
SOURCE 272 findings

Chen, Qing-Xin et al.. Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.. Endocrine. 2026.

Hypertension-related treatment-emergent adverse events with semaglutide in patients treated for T2DM or obesity; the overall association was not statistically significant (p=0.233), although the abstract noted unquantified potential protective signals in high-dose subgroups.

Added
RR 0.8195% CI: 0.57-1.15Source [27]

Hypotension-related treatment-emergent adverse events with semaglutide in patients treated for T2DM or obesity; the overall association was not statistically significant (p=0.232), although the abstract noted unquantified potential protective signals in high-dose subgroups.

Added
RR 1.3995% CI: 0.81-2.36Source [27]
SOURCE 262 findings

Murugadoss, Karthik et al.. GLP-1-based incretin therapy is associated with lower incident Alzheimer's disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk.. Biology methods & protocols. 2026.

First recorded Alzheimer's disease diagnosis after GLP-1-based incretin initiation versus non-GLP-1 antidiabetic medication initiation in the primary matched cohort of adults aged at least 50 years with a documented Alzheimer's disease risk factor; class-level observational association.

Added
HR 0.4695% CI: 0.29-0.73Source [26]

First recorded Alzheimer's disease diagnosis among semaglutide initiators versus matched non-GLP-1 antidiabetic medication initiators in an observational analysis with 23,675 patients per arm; q=0.02.

Added
SOURCE 254 findings

Tseng, Ting-Chun et al.. Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2026.

Composite cardiovascular outcome with metabolic and bariatric surgery versus semaglutide during up to 5 years of follow-up among adults with obesity without T2DM.

Added
HR 0.402; 4.4% vs 6.6%95% CI: 0.356-0.454Source [25]

Composite cardiovascular outcome with metabolic and bariatric surgery versus semaglutide during up to 5 years of follow-up among adults with obesity and T2DM.

Added
HR 0.421; 9.0% vs 14.6%95% CI: 0.381-0.465Source [25]
All 4 findings from this source

Heart-failure risk with metabolic and bariatric surgery versus semaglutide among adults with obesity without T2DM.

Added
HR 0.293Source [25]

Heart-failure risk with metabolic and bariatric surgery versus semaglutide among adults with obesity and T2DM.

Added
HR 0.346Source [25]
SOURCE 243 findings

Guo, Lixin et al.. Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.. The lancet. Diabetes & endocrinology. 2026.

Week-44 bodyweight change with once-weekly subcutaneous semaglutide 2.4 mg versus placebo, both plus lifestyle intervention, in adults from mainland China and Taiwan meeting local overweight or obesity BMI criteria; missing data were imputed with washout multiple imputation.

Added
-12.1% vs -2.2%; estimated treatment difference -9.9 percentage points95% CI: -11.8 to -8.0 percentage pointsSource [24]

Odds of achieving at least 5% bodyweight reduction by week 44 with semaglutide 2.4 mg versus placebo, both plus lifestyle intervention, in adults from mainland China and Taiwan meeting local overweight or obesity BMI criteria.

Added
OR 14.8; 80.5% vs 24.4%95% CI: 7.4 to 29.6Source [24]
All 3 findings from this source

Descriptive incidence of any adverse event with semaglutide 2.4 mg versus placebo among participants receiving treatment; gastrointestinal disorders were the most common adverse events.

Added
87.6% (141/161) vs 75.3% (61/81)Source [24]
SOURCE 233 findings

Jiménez-Mausbach, Martí et al.. Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial.. Alzheimer's & dementia (Amsterdam, Netherlands). 2026.

Increase through week 104 in dSST-predicted 5-year dementia risk with semaglutide versus placebo among adults aged at least 65 years with overweight or obesity and cardiovascular disease without diabetes; this represented a 26.0% lower predicted event rate and a 2.5-fold smaller increase.

Added
OR 0.7495% CI: 0.65-0.85Source [23]

Increase through week 104 in dSST-predicted 20-year dementia risk with semaglutide versus placebo among adults aged at least 65 years with overweight or obesity and cardiovascular disease without diabetes; this represented an 8.8% lower predicted risk and a 1.67-fold smaller increase.

Added
OR 0.9195% CI: 0.88-0.94Source [23]
All 3 findings from this source

Reduction in the odds of a higher dSST dementia-risk classification with semaglutide versus placebo in the post hoc SELECT analysis; β=-0.44 and P<0.001.

Added
SOURCE 211 finding

Qasim, Abeer et al.. The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents.. Frontiers in gastroenterology (Lausanne, Switzerland). 2026.

MASH resolution with semaglutide 2.4 mg versus placebo in the ESSENCE trial

Added
28.7% delta over placeboSource [21]
SOURCE 222 findings

Mann, Johannes F E et al.. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.. The lancet. Diabetes & endocrinology. 2026.

Primary composite of persistent ≥50% eGFR reduction, kidney failure, kidney-related death, or cardiovascular-related death with semaglutide versus placebo in the prespecified pooled SELECT, FLOW, and SOUL analysis; 973 versus 1134 first events. The trials differed in participants' baseline characteristics and in semaglutide dose and route.

Added
HR 0.8495% CI: 0.77-0.91Source [22]

Narrower secondary kidney composite excluding cardiovascular-related death with semaglutide versus placebo in the prespecified pooled SELECT, FLOW, and SOUL analysis; 347 versus 416 first events. The trials differed in participants' baseline characteristics and in semaglutide dose and route.

Added
HR 0.8095% CI: 0.69-0.92Source [22]
SOURCE 181 finding

Pałka, Wiktoria et al.. Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.. Journal of endocrinological investigation. 2026.

Average incremental efficacy benefit of semaglutide 7.2 mg over 2.4 mg over at least one year; the benefit was characterized as modest, percentage-bodyweight superiority was significant only in the diabetes subgroup, and tolerability and patient preferences should be considered.

Added
~2-3 percentage pointsSource [18]
SOURCE 196 findings

Roland, Noémie et al.. Impact of semaglutide introduction on the use of triptans: an interrupted-time series.. The journal of headache and pain. 2026.

Post-initiation trend in monthly triptan consumption after weight-management semaglutide initiation.

Added
-13 DDD/month/10,000 individuals95% CI: -25 to -1.3Source [19]

Relative reduction in triptan consumption at 12 months after semaglutide initiation in the interrupted-time-series analysis.

Added
RR 0.93 (7% relative reduction)95% CI: 0.88-0.97Source [19]
All 6 findings from this source

Reduction in triptan consumption among prevalent users; the abstract attributes the overall decrease mainly to lower consumption among existing users rather than a change in monthly rates of new users.

Added
RR 0.8695% CI: 0.82-0.90Source [19]

Female subgroup estimate for triptan consumption; males showed no statistically significant change, although no interaction statistic was reported.

Added
RR 0.92 (8% reduction)95% CI: 0.88-0.97Source [19]

Triptan-consumption reduction among semaglutide initiators aged 18-35 years.

Added
RR 0.8695% CI: 0.78-0.94Source [19]

Triptan-consumption reduction among semaglutide initiators with previous prophylactic antimigraine medication use.

Added
RR 0.8895% CI: 0.82-0.94Source [19]
SOURCE 203 findings

Kamrul-Hasan, A B M et al.. Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.. Obesity science & practice. 2026.

Percent body-weight change with high-dose oral semaglutide versus placebo in adults with overweight or obesity without diabetes; low-to-moderate-certainty network estimate, with comparative inference constrained by the absence of head-to-head trials.

Added
MD -11.6%Source [20]

BMI change with high-dose oral semaglutide versus placebo in adults with overweight or obesity without diabetes; low-to-moderate-certainty network estimate, with no head-to-head comparisons.

Added
MD -4.7 kg/m²Source [20]
All 3 findings from this source

Waist-circumference change with high-dose oral semaglutide versus placebo in adults with overweight or obesity without diabetes; low-to-moderate-certainty network estimate, with no head-to-head comparisons.

Added
MD -10.0 cmSource [20]
SOURCE 179 findings

Dutta, Deep et al.. Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2026.

Pooled mean body-weight reduction after 3 months of semaglutide in patients with ESRD; I²=58.1%.

Added
-3.09 kg95% CI: -5.95 to -0.24Source [17]

Pooled mean body-weight reduction after 6 months of semaglutide in patients with ESRD; I²=0.0%.

Added
-3.68 kg95% CI: -5.71 to -1.65Source [17]
All 9 findings from this source

Pooled mean body-weight reduction after 12 months of semaglutide in patients with ESRD; heterogeneity was substantial (I²=79.2%).

Added
-7.00 kg95% CI: -11.38 to -2.61Source [17]

Pooled HbA1c reduction after 6 months of semaglutide in patients with ESRD; the confidence interval included zero and I²=0.0%.

Added
-0.50%95% CI: -1.20% to 0.20%Source [17]

Pooled HbA1c reduction after 12 months of semaglutide in patients with ESRD; I²=61.6%.

Added
-0.75%95% CI: -1.07% to -0.43%Source [17]

Pooled absolute proportion of semaglutide-treated patients with ESRD experiencing gastrointestinal adverse events; I²=48.8%.

Added
39%95% CI: 25% to 55%Source [17]

Pooled absolute proportion of semaglutide-treated patients with ESRD experiencing nausea; the estimate was highly imprecise and heterogeneous (I²=73.6%).

Added
36%95% CI: 3% to 91%Source [17]

Pooled absolute proportion of semaglutide-treated patients with ESRD experiencing vomiting; I²=0.0%, although the confidence interval was wide.

Added
13%95% CI: 2% to 53%Source [17]

Pooled absolute proportion of semaglutide-treated patients with ESRD discontinuing treatment because of adverse events; I²=60.3%.

Added
9%95% CI: 4% to 20%Source [17]
SOURCE 164 findings

Thorsteinsdottir, Sigrun et al.. Real-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study.. Pediatric obesity. 2026.

Model-estimated reduction at six months in %IOTF30, defined as BMI expressed as a percentage of the age- and sex-specific IOTF obesity threshold.

Added
5.17 pp reduction at 6 months95% CI: 3.98 to 6.36Source [16]

Model-estimated reduction at 12 months in %IOTF30, defined as BMI expressed as a percentage of the age- and sex-specific IOTF obesity threshold.

Added
10.33 pp reduction at 12 months95% CI: 7.96 to 12.71Source [16]
All 4 findings from this source

Proportion of participants who achieved a reduction in %IOTF30 exceeding 10 percentage points.

Added

No statistically significant modification of treatment response by neurodevelopmental-disorder status was detected among 56 Pediatric Obesity Center participants; the analysis was underpowered and should not be interpreted as evidence of equivalent response.

Added
interaction p=0.83Source [16]
SOURCE 152 findings

Naz, Faryal et al.. Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.. Medicine. 2026.

Percentage change in body weight with subcutaneous semaglutide versus placebo in adults with overweight or obesity without type 2 diabetes

Added
MD -11.85%95% CI: -12.81% to -10.90%Source [15]

Treatment discontinuation due to adverse events with subcutaneous semaglutide versus placebo in adults with overweight or obesity without type 2 diabetes

Added
RR 2.6295% CI: 1.70-4.03Source [15]
SOURCE 141 finding

Patel, Henna et al.. Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.. Cureus. 2026.

Pooled mean percentage body-weight regain from end of treatment to follow-up after stopping semaglutide 2.4 mg, based on six studies

Added
7.19%95% CI: 6.42-7.96Source [14]
SOURCE 122 findings

Hwang, Inyoung et al.. Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.. Drug design, development and therapy. 2026.

Adjusted relative likelihood of achieving ≥15% weight loss with semaglutide versus liraglutide among adults with obesity in a retrospective real-world cohort.

Added
aHR 1.7795% CI: 1.56-2.01Source [12]

Mean weight change at 12 months among semaglutide initiators with obesity in a retrospective real-world cohort.

Added
SOURCE 135 findings

Schacht, Joseph P et al.. Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.. The American journal of psychiatry. 2026.

Key preregistered secondary outcome of heavy drinking days during the last 4 treatment weeks with oral semaglutide versus placebo in treatment-seeking adults with moderate-to-severe alcohol use disorder; laboratory-assessed craving and drinks per day were not significantly reduced.

Added
b=-0.58095% CI: -1.012 to -0.148Source [13]

Exploratory effect on drinks per drinking day with oral semaglutide versus placebo in adults with alcohol use disorder.

Added
b=-1.17795% CI: -2.307 to -0.047Source [13]
All 5 findings from this source

Exploratory difference in the rate of reduction in alcohol-related negative consequences with oral semaglutide versus placebo.

Added
b=-4.61895% CI: -8.651 to -0.585Source [13]

Exploratory comparison of the proportion reducing World Health Organization risk drinking level by at least one category with oral semaglutide versus placebo; the abstract did not report group percentages.

Added
Wald χ2=4.01Source [13]

Exploratory effect on cannabis-use days with oral semaglutide versus placebo among adults enrolled for alcohol use disorder.

Added
b=-1.43495% CI: -2.568 to -0.301Source [13]
SOURCE 116 findings

Rodbard, Helena W et al.. Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).. Diabetes, obesity & metabolism. 2026.

Severe hypoglycaemia occurred at a lower rate with semaglutide 2.0 mg plus dose-reduced insulin glargine versus dose-titrated insulin glargine at 40 weeks (p=0.02).

Added
Rate ratio 0.4595% CI: 0.23-0.87Source [11]

Gastrointestinal adverse-event counts were higher with semaglutide 2.0 mg plus dose-reduced insulin glargine than with dose-titrated insulin glargine; these are event counts rather than participant-level incidence rates, and the abstract reported no new safety concerns.

Added
310 vs. 32 eventsSource [11]
All 6 findings from this source

HbA1c reduction with semaglutide 2.0 mg plus dose-reduced insulin glargine versus dose-titrated insulin glargine at 40 weeks

Added
ETD -0.74%95% CI: -0.90% to -0.59%Source [11]

Body-weight change with semaglutide 2.0 mg plus dose-reduced insulin glargine versus dose-titrated insulin glargine at 40 weeks

Added
ETD -8.5 kg95% CI: -9.5 to -7.4 kgSource [11]

Relative daily insulin-dose change with semaglutide 2.0 mg plus dose-reduced insulin glargine versus dose-titrated insulin glargine at 40 weeks

Added
ETD -121.9%95% CI: -143.1% to -100.6%Source [11]

Diabetes Treatment Satisfaction Questionnaire change score with semaglutide 2.0 mg plus dose-reduced insulin glargine versus dose-titrated insulin glargine at 40 weeks

Added
ETD 2.695% CI: 1.6 to 3.5Source [11]
SOURCE 093 findings

Aljulajil, Faisal A et al.. Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.. Cureus. 2026.

HbA1c reduction with once-weekly semaglutide 1.0 mg versus insulin glargine or other GLP-1 receptor agonists in insulin-naive adults with T2DM uncontrolled on oral drugs; low-certainty evidence

Added
MD -0.64%95% CI: -0.80 to -0.47Source [9]

Body-weight change with semaglutide versus other GLP-1 receptor agonists; I²=0% and moderate-certainty evidence

Added
MD -3.72 kg95% CI: -4.17 to -3.28Source [9]
All 3 findings from this source

Hypoglycemia risk with semaglutide versus insulin glargine; moderate-certainty evidence

Added
RR 0.53Source [9]
SOURCE 105 findings

Khan, Suleman et al.. Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.. Medicine. 2026.

Pooled change in AST with subcutaneous semaglutide versus placebo among adults with NAFLD or NASH

Added
MD -6.72 U/L95% CI: -11.79 to -1.64Source [10]

NASH resolution without fibrosis progression with subcutaneous semaglutide versus placebo

Added
RR 2.1495% CI: 1.44-3.17Source [10]
All 5 findings from this source

Fibrosis-stage improvement with subcutaneous semaglutide versus placebo; the pooled result was not statistically significant

Added
RR 1.1495% CI: 0.63-2.05Source [10]

Pooled weight change with subcutaneous semaglutide versus placebo among adults with NAFLD or NASH; P = .05

Added
MD -6.99%95% CI: -13.92 to -0.06Source [10]

Pooled HbA1c change with subcutaneous semaglutide versus placebo among adults with NAFLD or NASH

Added
MD -1.29%95% CI: -1.46 to -1.13Source [10]
SOURCE 087 findings

Azzam, Ahmed Y et al.. Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.. JACC. Advances. 2026.

One-year heart-failure risk with tirzepatide versus semaglutide among patients with type 2 diabetes

Added
RR 0.8295% CI: 0.78-0.86Source [8]

Reported one-year heart-failure risk difference between tirzepatide and semaglutide among patients with type 2 diabetes, favoring tirzepatide

Added
All 7 findings from this source

One-year heart-failure risk with tirzepatide versus semaglutide among patients without diabetes

Added
RR 0.6095% CI: 0.55-0.65Source [8]

Reported one-year heart-failure risk difference between tirzepatide and semaglutide among patients without diabetes, favoring tirzepatide

Added

Effect modification by diabetes status for atrial fibrillation at 1 year

Added
P = 0.003Source [8]

Effect modification by diabetes status for heart failure at 1 year

Added
P < 0.001Source [8]

Effect modification by diabetes status for acute myocardial infarction at 1 year

Added
P = 0.019Source [8]
SOURCE 074 findings

Inzucchi, Silvio E et al.. Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?. The Journal of clinical endocrinology and metabolism. 2026.

Oral semaglutide reduced risk of major adverse cardiovascular events in SOUL trial

Added
14% MACE reductionSource [7]

MACE benefits varied significantly by baseline HbA1c, greater at higher baseline HbA1c

Added
P-interaction = .04Source [7]
All 4 findings from this source

Greater HbA1c reductions at 13 and 52 weeks associated with larger MACE risk decreases

Added
P-interactions .005 and < .001Source [7]

MACE benefits were consistent across BMI changes at weeks 13 and 52

Added
P-interactions .88 and .64Source [7]
SOURCE 053 findings

Cannon, Ethan J et al.. Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.. British journal of clinical pharmacology. 2026.

Incident diabetes risk with semaglutide versus liraglutide (overall)

Added
HR 0.8895% CI: 0.78, 0.99Source [5]

Incident diabetes risk with semaglutide versus liraglutide (first 6 months)

Added
HR 0.9995% CI: 0.82-1.18Source [5]
All 3 findings from this source

Cardiovascular disease risk with semaglutide versus liraglutide

Added
HR 1.2595% CI: 0.74-2.11Source [5]
SOURCE 065 findings

Zhou, Xiao-Yu et al.. Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2026.

Myocardial infarction reduction with semaglutide (updated estimate from meta-analysis)

Added
RR 0.7095% CI: 0.62-0.80Source [6]

Broad CAD-related composite outcome with semaglutide

Added
RR 0.8095% CI: 0.73-0.87Source [6]
All 5 findings from this source

Acute coronary syndrome reduction with semaglutide

Added
RR 0.7795% CI: 0.70-0.85Source [6]

Unstable angina reduction with semaglutide

Added
RR 0.8295% CI: 0.70-0.96Source [6]

Angina pectoris reduction with semaglutide

Added
RR 0.7395% CI: 0.60-0.89Source [6]
SOURCE 034 findings

Ahmed, Faizan et al.. GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.. Journal of clinical medicine. 2026.

All-cause mortality with incretin-based therapy vs SGLT2i in AF/HFpEF patients

Added
HR 0.72195% CI 0.634-0.820Source [3]

Myocardial infarction with incretin-based therapy vs SGLT2i in AF/HFpEF patients

Added
HR 0.583Source [3]
All 4 findings from this source

Major adverse cardiovascular events with incretin-based therapy vs SGLT2i in AF/HFpEF patients

Added
HR 0.709Source [3]

Absolute all-cause mortality rates at 1 year (incretin vs SGLT2i)

Added
5.3% vs. 7.3%Source [3]
SOURCE 042 findings

Loomba, Rohit et al.. Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.. The lancet. Gastroenterology & hepatology. 2026.

Proportion achieving improvement in liver fibrosis without MASH worsening with semaglutide 2.4mg versus placebo at week 52 in MASH patients with F2-F4c fibrosis

Added
30% vs 16%95% CI: 1.88 to 26.23 (EDP)Source [4]

Proportion achieving improvement in liver fibrosis without MASH worsening with zalfermin 30mg plus semaglutide 2.4mg versus placebo (non-significant)

Added
24% vs 16%95% CI: -3.82 to 19.79 (EDP)Source [4]
SOURCE 017 findings

Nong, Kailei et al.. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.. BMJ (Clinical research ed.). 2026.

One-year weight loss with oral semaglutide versus lifestyle modification alone

Added
-10.9%95% CI: -12.7% to -9.1%Source [1]

One-year weight loss with subcutaneous semaglutide versus lifestyle modification alone

Added
-9.8%95% CI: -10.6% to -9.1%Source [1]
All 7 findings from this source

All-cause mortality reduction with subcutaneous semaglutide (only drug with this benefit)

Added
RR 0.8195% CI: 0.72 to 0.93Source [1]

Myocardial infarction reduction with subcutaneous semaglutide

Added
RR 0.7295% CI: 0.61 to 0.85Source [1]

Heart failure risk reduction with subcutaneous semaglutide

Added
RR 0.4395% CI: 0.21 to 0.84Source [1]

Discontinuation due to adverse events with oral semaglutide (range across drugs)

Added
RR 1.9 to 4.2Source [1]

Gastrointestinal events with oral semaglutide (range across drugs)

Added
RR 3.1 to 4.2Source [1]
SOURCE 024 findings

Chen, Hsin-Yu et al.. Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2026.

Femoral fracture risk with semaglutide versus DPP-4 inhibitors in older adults with T2DM and overweight/obesity

Added
HR 0.48895% CI: 0.367-0.649Source [2]

Fall risk with semaglutide versus DPP-4 inhibitors in older adults with T2DM and overweight/obesity

Added
HR 0.66395% CI: 0.612-0.718Source [2]
All 4 findings from this source

Absolute femoral fracture rates with semaglutide versus DPP-4 inhibitors

Added
0.3% vs. 0.5%Source [2]

Absolute fall rates with semaglutide versus DPP-4 inhibitors

Added
3.6% vs. 5.4%Source [2]
Browse the 38 original sourcesThe full bibliography behind this monitor.
  1. [1]

    Nong, Kailei et al.. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.. BMJ (Clinical research ed.). 2026.

    Open original source in a new tab
  2. [2]

    Chen, Hsin-Yu et al.. Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2026.

    Open original source in a new tab
  3. [3]

    Ahmed, Faizan et al.. GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.. Journal of clinical medicine. 2026.

    Open original source in a new tab
  4. [4]

    Loomba, Rohit et al.. Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.. The lancet. Gastroenterology & hepatology. 2026.

    Open original source in a new tab
  5. [5]

    Cannon, Ethan J et al.. Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.. British journal of clinical pharmacology. 2026.

    Open original source in a new tab
  6. [6]

    Zhou, Xiao-Yu et al.. Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2026.

    Open original source in a new tab
  7. [7]

    Inzucchi, Silvio E et al.. Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?. The Journal of clinical endocrinology and metabolism. 2026.

    Open original source in a new tab
  8. [8]

    Azzam, Ahmed Y et al.. Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.. JACC. Advances. 2026.

    Open original source in a new tab
  9. [9]

    Aljulajil, Faisal A et al.. Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.. Cureus. 2026.

    Open original source in a new tab
  10. [10]

    Khan, Suleman et al.. Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.. Medicine. 2026.

    Open original source in a new tab
  11. [11]

    Rodbard, Helena W et al.. Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).. Diabetes, obesity & metabolism. 2026.

    Open original source in a new tab
  12. [12]

    Hwang, Inyoung et al.. Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.. Drug design, development and therapy. 2026.

    Open original source in a new tab
  13. [13]

    Schacht, Joseph P et al.. Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.. The American journal of psychiatry. 2026.

    Open original source in a new tab
  14. [14]

    Patel, Henna et al.. Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.. Cureus. 2026.

    Open original source in a new tab
  15. [15]

    Naz, Faryal et al.. Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.. Medicine. 2026.

    Open original source in a new tab
  16. [16]

    Thorsteinsdottir, Sigrun et al.. Real-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study.. Pediatric obesity. 2026.

    Open original source in a new tab
  17. [17]

    Dutta, Deep et al.. Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2026.

    Open original source in a new tab
  18. [18]

    Pałka, Wiktoria et al.. Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.. Journal of endocrinological investigation. 2026.

    Open original source in a new tab
  19. [19]

    Roland, Noémie et al.. Impact of semaglutide introduction on the use of triptans: an interrupted-time series.. The journal of headache and pain. 2026.

    Open original source in a new tab
  20. [20]

    Kamrul-Hasan, A B M et al.. Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.. Obesity science & practice. 2026.

    Open original source in a new tab
  21. [21]

    Qasim, Abeer et al.. The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents.. Frontiers in gastroenterology (Lausanne, Switzerland). 2026.

    Open original source in a new tab
  22. [22]

    Mann, Johannes F E et al.. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.. The lancet. Diabetes & endocrinology. 2026.

    Open original source in a new tab
  23. [23]

    Jiménez-Mausbach, Martí et al.. Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial.. Alzheimer's & dementia (Amsterdam, Netherlands). 2026.

    Open original source in a new tab
  24. [24]

    Guo, Lixin et al.. Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.. The lancet. Diabetes & endocrinology. 2026.

    Open original source in a new tab
  25. [25]

    Tseng, Ting-Chun et al.. Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2026.

    Open original source in a new tab
  26. [26]

    Murugadoss, Karthik et al.. GLP-1-based incretin therapy is associated with lower incident Alzheimer's disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk.. Biology methods & protocols. 2026.

    Open original source in a new tab
  27. [27]

    Chen, Qing-Xin et al.. Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.. Endocrine. 2026.

    Open original source in a new tab
  28. [28]

    Ayoub, Malek et al.. Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.. Alimentary pharmacology & therapeutics. 2026.

    Open original source in a new tab
  29. [29]

    Plutzky, Jorge et al.. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.. Circulation. 2026.

    Open original source in a new tab
  30. [30]

    Khani, Elnaz et al.. Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.. Journal of clinical pharmacology. 2026.

    Open original source in a new tab
  31. [31]

    Banerjee, Mainak et al.. Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.. Obesity (Silver Spring, Md.). 2026.

    Open original source in a new tab
  32. [32]

    McIntyre, Roger S et al.. Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.. JAMA psychiatry. 2026.

    Open original source in a new tab
  33. [33]

    Zinzi, Alessia et al.. Semaglutide Exposure During Pregnancy: Results from the FAERS Database.. Pharmaceuticals (Basel, Switzerland). 2026.

    Open original source in a new tab
  34. [34]

    Moiz, Areesha et al.. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.. Annals of internal medicine. 2026.

    Open original source in a new tab
  35. [35]

    Kow, Chia Siang et al.. Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.

    Open original source in a new tab
  36. [36]

    Santos-Pereira, Mariana et al.. Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.

    Open original source in a new tab
  37. [37]

    Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.

    Open original source in a new tab
  38. [38]

    Moubarak, Elsayed S et al.. Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.. Journal of psychopharmacology (Oxford, England). 2026.

    Open original source in a new tab
ABOUT THIS MONITOR

The evidence, with its limits.

Study findings are generated with AI assistance and have not been reviewed by a clinician. The date on each finding records when it was added to this monitor; it is not the publication date or a clinical review date.

This monitor does not offer individual treatment advice. Bring personal health questions to a qualified clinician.